

Development of a Grant / Translational Idea

Sumit K. Subudhi, MD, PhD

Associate Professor

Genitourinary Medical Oncology

Disclosures

- **Consulting or Advisory Role:** Amgen, Apricity Health, AstraZeneca, Bayer, Bristol-Myers Squibb, Dava Oncology, Dendreon, Exelixis, Janssen Oncology, and Kahr
- **Research Funding:** AstraZeneca, Bristol-Myers Squibb, and Janssen Oncology
- **Other (Joint Scientific Committee):** Janssen Oncology, Polaris
- I **will** be discussing non-FDA approved indications during my presentation.

Where Do You Start?

- **High profile papers**
- **Scientific meetings**
- **Request for applications (RFA)**

Idea

- **Importance of an issue (e.g., Reducing mortality of immune-mediated myocarditis)**
- **Resolving a question (e.g., Why are bone and liver metastases resistant to immune checkpoint therapies)**
- **Find something surprising (e.g., B cells play an important role in response and toxicities to immune checkpoint therapies)**

Request for Application (RFA)

- **Details**
- **Funding**
- **Years**

Define Translational Research

- **Bench-Bedside**
- **Bedside-Bench-Bedside**
- **Bedside-Bedside**

Approach

- **Collaborators**
- **Resources (cell lines, animal models, patient samples, clinical trials)**
- **Technology (scRNA seq, ATAC-seq, CyTOF, multiplex immunofluorescence)**
- **Feasibility**